Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Dokumenty

Y0000773

Lansoprazole

European Pharmacopoeia (EP) Reference Standard

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C16H14F3N3O2S
Numer CAS:
103577-45-3
Masa cząsteczkowa:
369.36
Numer MDL:
MFCD00866873
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329831143
NACRES:
NA.24

klasa czystości

pharmaceutical primary standard

rodzina API

lansoprazole

producent / nazwa handlowa

EDQM

Zastosowanie

pharmaceutical (small molecule)

format

neat

ciąg SMILES

Cc1c(CS(=O)c2nc3ccccc3[nH]2)nccc1OCC(F)(F)F

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

Klucz InChI

MJIHNNLFOKEZEW-UHFFFAOYSA-N

informacje o genach

human ... ATP4A(495) , ATP4B(496)

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

Lansoprazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Opakowanie

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Inne uwagi

Sales restrictions may apply.
This page may contain text that has been machine translated.

produkt powiązany

Numer produktu
Opis
Cennik

Y0000774

Lansoprazole for peak identification, European Pharmacopoeia (EP) Reference Standard

1356916

Lansoprazole, United States Pharmacopeia (USP) Reference Standard

1356927

Lansoprazole Related Compound A, United States Pharmacopeia (USP) Reference Standard

1356931

Lansoprazole Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP872

Lansoprazole, British Pharmacopoeia (BP) Reference Standard

BP873

Lansoprazole impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR3019

Lansoprazole Related Compound A, pharmaceutical secondary standard, certified reference material

PHR2956

Lansoprazole Related Compound B, certified reference material, pharmaceutical secondary standard

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 2

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable

Choose from one of the most recent versions:

Certyfikaty analizy (CoA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

D A Peura et al.
Alimentary pharmacology & therapeutics, 37(8), 810-818 (2013-03-05)
Higher body mass index (BMI) is a recognised risk factor for gastro-oesophageal reflux disease (GERD). Data regarding the impact of BMI on proton pump inhibitor (PPI) therapy are conflicting. To assess the impact of BMI on baseline heartburn symptom severity
Grace Chai et al.
Pediatrics, 130(1), 23-31 (2012-06-20)
To describe trends in outpatient prescription drug utilization in US children and the changes in major areas of pediatric therapeutic use for the years 2002 through 2010. Large prescription databases (the IMS Vector One: National and Total Patient Tracker) were
Hala H Mosli et al.
The Journal of clinical endocrinology and metabolism, 97(9), E1731-E1735 (2012-06-23)
Chromogranin A (CgA) is used as a generic tumor marker for neuroendocrine tumors. Proton pump inhibitors (PPI) are known to increase CgA, but it is not clear to what extent, and there is little information on how long PPI need
Nahuai Badiola et al.
PloS one, 8(3), e58837-e58837 (2013-03-23)
A key event in the pathogenesis of Alzheimer's disease (AD) is the accumulation of amyloid-β (Aβ) species in the brain, derived from the sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretases. Based on a systems biology
Jyh-Ming Liou et al.
Lancet (London, England), 381(9862), 205-213 (2012-11-20)
Whether sequential treatment can replace triple therapy as the standard treatment for Helicobacter pylori infection is unknown. We compared the efficacy of sequential treatment for 10 days and 14 days with triple therapy for 14 days in first-line treatment. For
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej